Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
MNTA's Cash-to-Debt is ranked higher than
99% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. MNTA: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
MNTA' s Cash-to-Debt Range Over the Past 10 Years
Min: 10.74  Med: 123.74 Max: No Debt
Current: No Debt
Equity-to-Asset 0.72
MNTA's Equity-to-Asset is ranked higher than
63% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. MNTA: 0.72 )
Ranked among companies with meaningful Equity-to-Asset only.
MNTA' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.49  Med: 0.85 Max: 0.96
Current: 0.72
-0.49
0.96
Interest Coverage No Debt
MNTA's Interest Coverage is ranked higher than
99% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 106.84 vs. MNTA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MNTA' s Interest Coverage Range Over the Past 10 Years
Min: 110.84  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 3.44
Beneish M-Score: -4.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -106.52
MNTA's Operating Margin % is ranked lower than
86% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. MNTA: -106.52 )
Ranked among companies with meaningful Operating Margin % only.
MNTA' s Operating Margin % Range Over the Past 10 Years
Min: -448.33  Med: -142.21 Max: 63.48
Current: -106.52
-448.33
63.48
Net Margin % -55.61
MNTA's Net Margin % is ranked lower than
82% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. MNTA: -55.61 )
Ranked among companies with meaningful Net Margin % only.
MNTA' s Net Margin % Range Over the Past 10 Years
Min: -429.9  Med: -140.82 Max: 63.71
Current: -55.61
-429.9
63.71
ROE % -16.61
MNTA's ROE % is ranked lower than
77% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. MNTA: -16.61 )
Ranked among companies with meaningful ROE % only.
MNTA' s ROE % Range Over the Past 10 Years
Min: -66.11  Med: -31.66 Max: 59.21
Current: -16.61
-66.11
59.21
ROA % -12.31
MNTA's ROA % is ranked lower than
77% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. MNTA: -12.31 )
Ranked among companies with meaningful ROA % only.
MNTA' s ROA % Range Over the Past 10 Years
Min: -51.08  Med: -27.29 Max: 55.62
Current: -12.31
-51.08
55.62
ROC (Joel Greenblatt) % -467.19
MNTA's ROC (Joel Greenblatt) % is ranked lower than
89% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. MNTA: -467.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MNTA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -529.82  Med: -376.75 Max: 349.83
Current: -467.19
-529.82
349.83
3-Year Revenue Growth Rate 31.80
MNTA's 3-Year Revenue Growth Rate is ranked higher than
92% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. MNTA: 31.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MNTA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0.5 Max: 139.6
Current: 31.8
0
139.6
3-Year EBITDA Growth Rate -21.70
MNTA's 3-Year EBITDA Growth Rate is ranked lower than
89% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. MNTA: -21.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MNTA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -47.6  Med: -11 Max: 30.4
Current: -21.7
-47.6
30.4
3-Year EPS without NRI Growth Rate -47.40
MNTA's 3-Year EPS without NRI Growth Rate is ranked lower than
95% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. MNTA: -47.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MNTA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.2  Med: -10.2 Max: 30.1
Current: -47.4
-48.2
30.1
GuruFocus has detected 1 Warning Sign with Momenta Pharmaceuticals Inc MNTA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MNTA's 30-Y Financials

Financials (Next Earnings Date: 2018-02-21)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

MNTA Guru Trades in Q4 2016

Jim Simons 397,100 sh (+35.62%)
Paul Tudor Jones 23,129 sh (+17.22%)
PRIMECAP Management 2,739,900 sh (unchged)
» More
Q1 2017

MNTA Guru Trades in Q1 2017

PRIMECAP Management 2,739,900 sh (unchged)
Paul Tudor Jones 19,100 sh (-17.42%)
Jim Simons 278,400 sh (-29.89%)
» More
Q2 2017

MNTA Guru Trades in Q2 2017

Jim Simons 797,400 sh (+186.42%)
PRIMECAP Management 2,839,900 sh (+3.65%)
Paul Tudor Jones Sold Out
» More
Q3 2017

MNTA Guru Trades in Q3 2017

Ken Fisher 98,523 sh (New)
Jim Simons 1,448,500 sh (+81.65%)
PRIMECAP Management 2,838,900 sh (-0.04%)
» More
» Details

Insider Trades

Latest Guru Trades with MNTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-09-30 New Buy$15.3 - $19.05 $ 13.70-18%98,523
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325414    SIC: 2836
Compare:ISX:KAEF, SHSE:603456, TPE:6452, SZSE:002365, SHSE:600829, SZSE:000650, SZSE:002349, NSE:STAR, SZSE:300485, SZSE:002880, SZSE:300039, SHSE:603676, SZSE:300683, ROCO:6446, SZSE:002550, BOM:524494, BOM:540596, XKRX:145020, SHSE:600351, TSX:GUD » details
Traded in other countries:LZ1.Germany,
Headquarter Location:USA
Momenta Pharmaceuticals Inc is a biotechnology company. It is engaged in developing generic versions of complex drugs, biosimilars and novel therapeutics for oncology and autoimmune disease.

Momenta is a biotechnology company based in Cambridge, Mass. Using technology developed at the Massachusetts Institute of Technology, it focuses on the characterization and development of innovative and complex generic drug molecules. Its first product was a bioequivalent generic version of Lovenox, sold through a partnership with Novartis. The company received an approval for the first generic version of Copaxone in early 2015, and has other innovative biologic drugs and biosimilars under development.

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 41.64
MNTA's Price-to-Owner-Earnings is ranked lower than
65% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.43 vs. MNTA: 41.64 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MNTA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.23  Med: 9.33 Max: 57.9
Current: 41.64
3.23
57.9
PB Ratio 2.90
MNTA's PB Ratio is ranked lower than
61% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. MNTA: 2.90 )
Ranked among companies with meaningful PB Ratio only.
MNTA' s PB Ratio Range Over the Past 10 Years
Min: 1.34  Med: 2.99 Max: 13.69
Current: 2.9
1.34
13.69
PS Ratio 9.00
MNTA's PS Ratio is ranked lower than
83% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. MNTA: 9.00 )
Ranked among companies with meaningful PS Ratio only.
MNTA' s PS Ratio Range Over the Past 10 Years
Min: 1.84  Med: 12.98 Max: 57.26
Current: 9
1.84
57.26
Price-to-Free-Cash-Flow 21.64
MNTA's Price-to-Free-Cash-Flow is ranked lower than
52% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.72 vs. MNTA: 21.64 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MNTA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.02  Med: 12.74 Max: 622.58
Current: 21.64
3.02
622.58
Price-to-Operating-Cash-Flow 17.19
MNTA's Price-to-Operating-Cash-Flow is ranked lower than
61% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.64 vs. MNTA: 17.19 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MNTA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.92  Med: 9.74 Max: 170.8
Current: 17.19
2.92
170.8
EV-to-EBIT -5.43
MNTA's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. MNTA: -5.43 )
Ranked among companies with meaningful EV-to-EBIT only.
MNTA' s EV-to-EBIT Range Over the Past 10 Years
Min: -52.4  Med: -4.7 Max: 16.9
Current: -5.43
-52.4
16.9
EV-to-EBITDA -5.82
MNTA's EV-to-EBITDA is ranked lower than
99.99% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. MNTA: -5.82 )
Ranked among companies with meaningful EV-to-EBITDA only.
MNTA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -80.3  Med: -5 Max: 15
Current: -5.82
-80.3
15
EV-to-Revenue 5.79
MNTA's EV-to-Revenue is ranked lower than
76% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. MNTA: 5.79 )
Ranked among companies with meaningful EV-to-Revenue only.
MNTA' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.9  Med: 9 Max: 55.2
Current: 5.79
0.9
55.2
Current Ratio 4.16
MNTA's Current Ratio is ranked higher than
69% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. MNTA: 4.16 )
Ranked among companies with meaningful Current Ratio only.
MNTA' s Current Ratio Range Over the Past 10 Years
Min: 1.71  Med: 10.19 Max: 28.87
Current: 4.16
1.71
28.87
Quick Ratio 4.16
MNTA's Quick Ratio is ranked higher than
75% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. MNTA: 4.16 )
Ranked among companies with meaningful Quick Ratio only.
MNTA' s Quick Ratio Range Over the Past 10 Years
Min: 1.71  Med: 10.19 Max: 28.87
Current: 4.16
1.71
28.87
Days Sales Outstanding 48.23
MNTA's Days Sales Outstanding is ranked lower than
55% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. MNTA: 48.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNTA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.32  Med: 86.25 Max: 233.89
Current: 48.23
36.32
233.89

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.80
MNTA's 3-Year Average Share Buyback Ratio is ranked lower than
69% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. MNTA: -10.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNTA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -659.5  Med: -10.8 Max: -1.7
Current: -10.8
-659.5
-1.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.78
MNTA's Price-to-Net-Cash is ranked higher than
77% of the 234 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.00 vs. MNTA: 3.78 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MNTA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.03  Med: 4.18 Max: 14.33
Current: 3.78
2.03
14.33
Price-to-Net-Current-Asset-Value 3.49
MNTA's Price-to-Net-Current-Asset-Value is ranked higher than
71% of the 474 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.23 vs. MNTA: 3.49 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MNTA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.55  Med: 3.6 Max: 11.36
Current: 3.49
1.55
11.36
Price-to-Tangible-Book 2.94
MNTA's Price-to-Tangible-Book is ranked lower than
51% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. MNTA: 2.94 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MNTA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.5  Med: 3.1 Max: 10.13
Current: 2.94
1.5
10.13
Price-to-Median-PS-Value 0.69
MNTA's Price-to-Median-PS-Value is ranked higher than
70% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. MNTA: 0.69 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MNTA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 1.07 Max: 4.17
Current: 0.69
0.14
4.17
Earnings Yield (Greenblatt) % -18.42
MNTA's Earnings Yield (Greenblatt) % is ranked lower than
85% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. MNTA: -18.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MNTA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -158.2  Med: -17.2 Max: 78.3
Current: -18.42
-158.2
78.3

More Statistics

Revenue (TTM) (Mil) $108.47
EPS (TTM) $ -0.80
Beta1.83
Short Percentage of Float13.93%
52-Week Range $11.85 - 19.90
Shares Outstanding (Mil)76.39

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 140 181 173 204
EPS ($) -1.29 -0.91 -1.41 -0.70
EPS without NRI ($) -1.29 -0.91 -1.41 -0.70
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}